Fulgent Genetics beats top-line and bottom-line estimates; reaffirms FY25 outlook
Source: SeekingAlpha
2025-05-02 07:02:20 ET
More on Fulgent Genetics
- Fulgent Genetics: Undervalued, CFO Buying, And Promising Drug Candidates Make It A Buy
- Fulgent Genetics, Inc. (FLGT) Q4 2024 Earnings Conference Call Transcript
- Fulgent Genetics Q1 2025 Earnings Preview
- Seeking Alpha’s Quant Rating on Fulgent Genetics
- Historical earnings data for Fulgent Genetics
Read the full article on Seeking Alpha
For further details see:
Fulgent Genetics beats top-line and bottom-line estimates; reaffirms FY25 outlook
Fulgent Genetics Inc.
NASDAQ: FLGT
FLGT Trading
3.59% G/L:
$14.855 Last:
371,380 Volume:
$14.66 Open:
FLGT Latest News
February 12, 2026 07:30:00 am
Fulgent to Announce Fourth Quarter and Full Year 2025 Financial Results on Friday, February 27, 2026
FLGT Stock Data
$726,441,212
20,677,299
5.21%
56
N/A
Medical Diagnostics & Screening
Healthcare
US
El Monte
